STRATA SKIN SCIENCES INC (SSKN) Fundamental Analysis & Valuation

NASDAQ:SSKN • US86272A3059

Current stock price

0.1898 USD
-0.13 (-39.99%)
At close:
0.159 USD
-0.03 (-16.23%)
After Hours:

This SSKN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SSKN Profitability Analysis

1.1 Basic Checks

  • SSKN had negative earnings in the past year.
  • In the past year SSKN has reported a negative cash flow from operations.
  • In the past 5 years SSKN always reported negative net income.
  • In multiple years SSKN reported negative operating cash flow during the last 5 years.
SSKN Yearly Net Income VS EBIT VS OCF VS FCFSSKN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

  • SSKN's Return On Assets of -35.94% is on the low side compared to the rest of the industry. SSKN is outperformed by 62.16% of its industry peers.
  • SSKN has a worse Return On Equity (-840.18%) than 84.86% of its industry peers.
Industry RankSector Rank
ROA -35.94%
ROE -840.18%
ROIC N/A
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
SSKN Yearly ROA, ROE, ROICSSKN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • SSKN has a Gross Margin of 57.76%. This is comparable to the rest of the industry: SSKN outperforms 58.92% of its industry peers.
  • In the last couple of years the Gross Margin of SSKN has declined.
  • SSKN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
SSKN Yearly Profit, Operating, Gross MarginsSSKN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. SSKN Health Analysis

2.1 Basic Checks

  • SSKN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SSKN has more shares outstanding
  • SSKN has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for SSKN is higher compared to a year ago.
SSKN Yearly Shares OutstandingSSKN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SSKN Yearly Total Debt VS Total AssetsSSKN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -11.29, we must say that SSKN is in the distress zone and has some risk of bankruptcy.
  • SSKN has a Altman-Z score of -11.29. This is in the lower half of the industry: SSKN underperforms 78.92% of its industry peers.
  • SSKN has a Debt/Equity ratio of 10.22. This is a high value indicating a heavy dependency on external financing.
  • SSKN has a worse Debt to Equity ratio (10.22) than 86.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 10.22
Debt/FCF N/A
Altman-Z -11.29
ROIC/WACCN/A
WACC10.67%
SSKN Yearly LT Debt VS Equity VS FCFSSKN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 0.95 indicates that SSKN may have some problems paying its short term obligations.
  • With a Current ratio value of 0.95, SSKN is not doing good in the industry: 87.57% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.75 indicates that SSKN may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.75, SSKN is doing worse than 85.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.75
SSKN Yearly Current Assets VS Current LiabilitesSSKN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. SSKN Growth Analysis

3.1 Past

  • The earnings per share for SSKN have decreased by -0.38% in the last year.
  • The Revenue has decreased by -5.19% in the past year.
  • Measured over the past years, SSKN shows a small growth in Revenue. The Revenue has been growing by 1.22% on average per year.
EPS 1Y (TTM)-0.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.08%
Revenue 1Y (TTM)-5.19%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-21.23%

3.2 Future

  • SSKN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.14% yearly.
  • The Revenue is expected to grow by 2.63% on average over the next years.
EPS Next Y29.66%
EPS Next 2Y21.43%
EPS Next 3Y17.14%
EPS Next 5YN/A
Revenue Next Year-7.22%
Revenue Next 2Y-0.28%
Revenue Next 3Y2.63%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SSKN Yearly Revenue VS EstimatesSSKN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
SSKN Yearly EPS VS EstimatesSSKN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

0

4. SSKN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SSKN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SSKN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SSKN Price Earnings VS Forward Price EarningsSSKN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SSKN Per share dataSSKN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SSKN's earnings are expected to grow with 17.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.43%
EPS Next 3Y17.14%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SSKN Dividend Analysis

5.1 Amount

  • No dividends for SSKN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SSKN Fundamentals: All Metrics, Ratios and Statistics

STRATA SKIN SCIENCES INC

NASDAQ:SSKN (2/18/2026, 8:03:01 PM)

After market: 0.159 -0.03 (-16.23%)

0.1898

-0.13 (-39.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13
Earnings (Next)03-25
Inst Owners19.58%
Inst Owner Change0%
Ins Owners0.18%
Ins Owner Change-0.24%
Market Cap1.12M
Revenue(TTM)30.98M
Net Income(TTM)-11.04M
Analysts85
Price Target7.55 (3877.87%)
Short Float %4.73%
Short Ratio0.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.02%
Min EPS beat(2)-104.6%
Max EPS beat(2)8.56%
EPS beat(4)1
Avg EPS beat(4)-94.34%
Min EPS beat(4)-271.14%
Max EPS beat(4)8.56%
EPS beat(8)2
Avg EPS beat(8)-98.86%
EPS beat(12)4
Avg EPS beat(12)-57.78%
EPS beat(16)7
Avg EPS beat(16)-39.57%
Revenue beat(2)0
Avg Revenue beat(2)-14.84%
Min Revenue beat(2)-17.42%
Max Revenue beat(2)-12.25%
Revenue beat(4)1
Avg Revenue beat(4)-8.34%
Min Revenue beat(4)-17.42%
Max Revenue beat(4)4.61%
Revenue beat(8)3
Avg Revenue beat(8)-8.04%
Revenue beat(12)4
Avg Revenue beat(12)-5.63%
Revenue beat(16)6
Avg Revenue beat(16)-2.84%
PT rev (1m)0%
PT rev (3m)-7.5%
EPS NQ rev (1m)21.58%
EPS NQ rev (3m)-4.88%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.01%
Revenue NQ rev (1m)8.09%
Revenue NQ rev (3m)2.12%
Revenue NY rev (1m)2.3%
Revenue NY rev (3m)-5.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.67
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS5.26
BVpS0.22
TBVpS-0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.94%
ROE -840.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.76%
FCFM N/A
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
F-Score3
Asset Turnover1.01
Health
Industry RankSector Rank
Debt/Equity 10.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.81%
Cap/Sales 5.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.95
Quick Ratio 0.75
Altman-Z -11.29
F-Score3
WACC10.67%
ROIC/WACCN/A
Cap/Depr(3y)63.47%
Cap/Depr(5y)69.64%
Cap/Sales(3y)9.91%
Cap/Sales(5y)10.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.08%
EPS Next Y29.66%
EPS Next 2Y21.43%
EPS Next 3Y17.14%
EPS Next 5YN/A
Revenue 1Y (TTM)-5.19%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-21.23%
Revenue Next Year-7.22%
Revenue Next 2Y-0.28%
Revenue Next 3Y2.63%
Revenue Next 5YN/A
EBIT growth 1Y-4.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year78.21%
EBIT Next 3Y84%
EBIT Next 5YN/A
FCF growth 1Y47.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.99%
OCF growth 3Y-50.07%
OCF growth 5Y-39.02%

STRATA SKIN SCIENCES INC / SSKN Fundamental Analysis FAQ

What is the fundamental rating for SSKN stock?

ChartMill assigns a fundamental rating of 1 / 10 to SSKN.


What is the valuation status for SSKN stock?

ChartMill assigns a valuation rating of 0 / 10 to STRATA SKIN SCIENCES INC (SSKN). This can be considered as Overvalued.


Can you provide the profitability details for STRATA SKIN SCIENCES INC?

STRATA SKIN SCIENCES INC (SSKN) has a profitability rating of 1 / 10.


What is the expected EPS growth for STRATA SKIN SCIENCES INC (SSKN) stock?

The Earnings per Share (EPS) of STRATA SKIN SCIENCES INC (SSKN) is expected to grow by 29.66% in the next year.